Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616555 | 0.84 | HDAC6 (0.72) | HDAC6TRPV1NPC1RAB9AKDM4E | |
| SCHEMBL19617670 | 0.84 | HDAC6 (1.00) | HDAC6NPC1RAB9AMEN1KMT2A | |
| SCHEMBL21369315 | 0.84 | HDAC6 (0.72) | HDAC6TRPV1 | |
| SCHEMBL846145 | 0.83 | KDR (0.72) | HDAC6TRPV1KDRNPC1RAB9A | |
| SCHEMBL29647749 | 0.83 | KDR (0.81) | HDAC6TRPV1KDRNPC1RAB9A | |
| SCHEMBL19616459 | 0.83 | KDR (0.81) | HDAC6TRPV1KDRNPC1RAB9A | |
| SCHEMBL4569181 | 0.82 | HDAC1 (0.71) | HDAC6 | |
| SCHEMBL19631297 | 0.81 | HDAC6 (0.69) | HDAC6NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL9093698 | 0.81 | HDAC6 (0.67) | HDAC6KDRNPC1RAB9AKDM4E | |
| SCHEMBL24522599 | 0.79 | HDAC6 (0.65) | HDAC6TRPV1KDRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346563-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | UNIV TAIPEI MEDICAL (TW) | 2025-11-13 | — | — | US | disclosed |
| US-11427544-B2 | Histone deacetylase 6 inhibitors and use thereof | TAIPEI MEDICAL UNIVERSITY (TW) | 2022-08-30 | — | — | US | disclosed |
| US-20220251043-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | TAIPEI MEDICAL UNIVERSITY (TW) | 2022-08-11 | — | — | US | disclosed |
| EP-3458444-B1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | UNIV TAIPEI MEDICAL (TW) | 2022-06-22 | — | — | EP | disclosed |
| EP-3458444-B1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | UNIV TAIPEI MEDICAL (TW) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021013163-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | TAIPEI MEDICAL UNIVERSITY (CN) | 2021-01-28 | — | — | WO | disclosed |
| US-20190284141-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | DCB-USA LLC (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284141-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | DCB-USA LLC (US) | 2019-09-19 | — | — | US | disclosed |
| EP-3458444-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | DCB-USA LLC (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017200966-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | DCB-USA LLC (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017200966-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | DCB-USA LLC (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284141-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | HDAC1, HDAC11, HDAC7 | HDAC6 7/4885TRPV1 4264/4885KDR 4795/4885 |
| US-20250346563-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | HDAC1, HDAC3, HDAC5 | HDAC6 4/4885TRPV1 494/4885KDR 4807/4885 |
| US-20220251043-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | HDAC1, HDAC3, HDAC2 | HDAC6 9/4885TRPV1 357/4885KDR 4819/4885 |
| US-11427544-B2 | Histone deacetylase 6 inhibitors and use thereof | HDAC1, HDAC11, HDAC7 | HDAC6 7/4885TRPV1 4264/4885KDR 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.